Pan-inhibitors that inhibit b-RAF proto-oncogene (BRAF) and c-RAF proto-oncogene (CRAF) as well as not activating the MAPK pathway in cancers harboring KRAS mutations are being generated and show in vitro promising results [44]. This evidence concerns the gene BRAF and cancer.